Phase 1 trial points to early promise for IMA401 in solid tumors

IMA401 posts early phase 1 signals in advanced solid tumors

A first-in-human study published in Nature Medicine is offering an early look at IMA401, a T cell receptor-based bispecific T cell engager designed for patients with recurrent or refractory solid tumors. The drug targets an HLA-A*02:01-presented peptide derived from MAGE-A4 and MAGE-A8, two tumor-associated antigens that have drawn interest as potential immunotherapy targets across multiple cancer types.

The interim analysis covered 61 patients with advanced solid tumors who received intravenous IMA401 across a dose range from 0.0066 mg to 2.5 mg, either alone or in combination with pembrolizumab. The trial’s primary objective was to determine the maximum tolerated dose or a recommended phase 2 dose for both monotherapy and combination treatment. Investigators reported that the maximum tolerated dose was not reached under the protocol definition, and identified a recommended phase 2 dose range of 1 mg to 2 mg given every two weeks.

Safety profile was manageable, with cytokine release syndrome largely low grade

Early safety findings are central in any first-in-human oncology study, and here the investigators said treatment-related adverse events were generally manageable. The most common treatment-related events of any grade were cytokine release syndrome in 38% of patients, transient lymphopenia in 33%, and reversible neutropenia in 31%.

Notably, the cytokine release syndrome cases were reported as grade 1 or grade 2 only. That matters because immune-engaging therapies often face scrutiny over whether their inflammatory side effects can be controlled in routine use. Five patients experienced dose-limiting toxicities, mainly linked to neutropenia. Researchers also reported that no further dose-limiting toxicities were seen in the recommended phase 2 dose range when dexamethasone premedication was used.

One death possibly related to treatment was reported outside the recommended phase 2 dose range, involving pneumonia in a patient with rapidly progressing lung metastases who received 2.5 mg of IMA401. The study’s framing suggests investigators see that event as important but not representative of the dose range they are advancing.

Why this drug candidate is drawing attention

IMA401 is built around a T cell receptor-based format rather than a conventional antibody-only design. According to the study abstract, it combines a high-affinity TCR-based targeting domain, a low-affinity T-cell-recruiting domain, and an optimized Fc domain intended to extend half-life. That architecture is meant to improve tumor targeting while keeping systemic immune activation within a tolerable range.

The target choice is also notable. MAGE-A4 and MAGE-A8 belong to a class of cancer-testis antigens that are expressed in a range of tumors while remaining limited in normal tissues, making them attractive but technically challenging targets. By going after a peptide presented by HLA-A*02:01, the therapy is tailored to a specific antigen presentation context rather than working as a broadly applicable drug for every patient.

That requirement narrows the eligible population, but it can also sharpen precision. In solid tumors, where many immunotherapies have shown uneven activity outside selected settings, a more targeted approach may help developers find clearer signals of benefit.

Early efficacy is encouraging, but still preliminary

The publication describes the analysis as prespecified and interim, which is an important limitation. At this stage, the purpose is not to establish definitive efficacy but to show whether the drug can be delivered safely enough, at meaningful doses, to justify larger trials. The efficacy-evaluable population included 56 patients across all dose levels, including very low starting doses that would not normally be expected to drive strong antitumor responses.

Even so, the study was presented at the 2026 ASCO Annual Meeting and published online as an open-access paper, both signs that the early data are considered meaningful within the oncology community. The practical question now is whether the activity seen in this first pass can hold up when patients are treated consistently in the recommended range and when the dataset grows beyond the exploratory stage.

That next step matters because many early immuno-oncology programs show intriguing response patterns before later studies reveal narrower benefit or more complicated tolerability issues. Dose optimization, patient selection, and management of immune-related toxicities will likely shape the development path from here.

What the phase 1 result means

The clearest takeaway is that IMA401 appears to have moved past the earliest feasibility test. Investigators found a recommended dose range, did not hit a protocol-defined maximum tolerated dose, and reported side effects that they describe as manageable with the right precautions. That is the baseline needed for a more serious phase 2 discussion.

It does not yet mean the therapy will become a new standard for solid tumors, or even that it will succeed in later-stage development. But it does place IMA401 among the more closely watched next-generation immune-engaging programs in a field still searching for ways to extend immunotherapy benefits beyond the cancers where checkpoint blockade has already become entrenched.

For patients with recurrent or refractory solid tumors, the unmet need remains substantial. Any therapy that can show a workable safety profile alongside early antitumor activity in that setting will get attention. IMA401 has now done enough to earn that attention, and the next readouts will determine whether it can translate a technically ambitious design into a clinically durable result.

This article is based on reporting by Nature Medicine. Read the original article.